-
-
-
-
-
-
-
Arvinas Reports First Quarter 2026 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Arvinas, Inc. (ARVN) Tops Q3 EPS by 23c
-
-
-
-
-
-
-
Arvinas and Pfizer's Vepdegestrant Significantly Improves Progression-Free Survival for Patients with ESR1-Mutant, ER+/HER2- Advanced Breast Cancer
-
-
-
-
-
-
-
Arvinas and Pfizer Announce Positive Topline Results from Phase 3 VERITAC-2 Clinical Trial
-
-
-
-
-
-
-
Arvinas Reports Third Quarter 2024 Financial Results and Provides Corporate Update
-
-
-
-
-
-
-
Arvinas, Inc. (ARVN) Tops Q1 EPS by 43c
-
-
-
-
-
-
-
Arvinas and Pfizer Announce Updated Vepdegestrant (ARV-471) Data to be Presented at the 2023 San Antonio Breast Cancer Symposium
-
1,215,883 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

